Use of Propranolol for Treating Hemangiomas in Infants with Previously Diagnosed Hypoglycemic Conditions

Area of Science:

• Pediatric vascular tumors
• Pharmacology
• Neonatal medicine

Background:

• Infantile hemangiomas (IHs) are common pediatric vascular tumors requiring treatment for severe complications.
• Propranolol is the FDA-approved first-line therapy for complicated IHs, but its use in infants with hypoglycemia is not well-documented.
• Existing therapies like corticosteroids and surgery are less common due to propranolol's efficacy and safety profile.

Observation:

• This study reports on three infants with pre-existing hypoglycemic conditions requiring diazoxide therapy.
• These infants presented with complicated infantile hemangiomas.
• Oral propranolol was administered to these infants for their IHs.

Findings:

• All three infants with infantile hemangiomas and pre-existing hypoglycemia were successfully treated with oral propranolol.
• Treatment with propranolol in this specific patient group did not result in significant adverse events.
• The study demonstrates the safety and efficacy of propranolol in managing IHs in infants with concurrent hypoglycemic conditions.

Implications:

• The findings suggest that propranolol can be a safe and effective treatment option for infantile hemangiomas even in infants with pre-existing hypoglycemic conditions.
• This expands the therapeutic possibilities for managing complicated IHs in a vulnerable pediatric population.
• Further research is warranted to confirm these findings in larger cohorts and establish specific monitoring guidelines.